CytRx, DevGen, Fisher Scientific, and Nature Reviews Drug Discovery | GenomeWeb

CytRx Says Accounting Review Delays Annual Report Filing

CytRx said last week in a filing with the US Securities and Exchange Commission that it was unable to file its annual report for the year 2003 by the March 30 deadline due to accounting issues related to two subsidiaries that the company has decided to write off.

In January, CytRx said that it had decided to end its investments in firms Blizzard Genomics and Psynomics, and that it would write off its ownership stakes in the two companies for a one-time fourth-quarter charge.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.